ong term prospective observational cohort study of the safety and efficacy of certolizumab pegol in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profile.
Recruiting
- Conditions
- certolizumab pegolrheumatoid arthritissafetyefficacyIn het Nederlandscertolizumab pegolreumatoide artritisveiligheideffectiviteit
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
1. Patients with rheumatoid arthritis in whom certolizumab pegol treatment is started;
2. Written informed consent.
Exclusion Criteria
None, except for the contraindications against certolizumab pegol treatment.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determinate the efficacy and safety of certolizumab pegol in rheumatoid arthritis patients in daily clinical practice during 48 months.
- Secondary Outcome Measures
Name Time Method The effect of treatment with certolizumab pegol on the lipid profile will be monitored during this study.